Canada markets open in 6 hours 17 minutes

ImmunoPrecise Antibodies Ltd. (IPA.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
8.69+0.12 (+1.40%)
At close: 3:54PM EDT
Sign in to post a message.
  • b
    beurs
    I sold my shares...took my loss..bad investment...
  • T
    Terry
    IPA has attracted the attention of someone with one of the biggest followings on Twitter for small caps. He is doing an interview on Weds with IPA Mgmt. This is the Tweet that explains today's volume and price, it has a link to the interview if you're interested: https://twitter.com/JonahLupton/status/1379118185526493184?s=20
  • A
    Azfar
    Interview with the CEO is up on Youtube. If you want to know what the company does in Layman's terms, I suggest checking out the interview: https://www.youtube.com/watch?v=HDNse6En8jU
    Interview with Dr. Jennifer Bath, CEO of ImmunoPrecise ($IPA)
    www.youtube.com
  • b
    beurs
    bought more today..will be smiling later...buy when there is fear..sell when there is hype..now we are in fear time in bio stock market
  • K
    Kev
    why people not holding lol for long terme...lots of weak minded short term
  • b
    beurs
    bought more today..soon is our turn
  • b
    beurs
    Shorts start covering..
  • R
    Remon
    ImmunoPrecise Reports Financial Results and Recent Business Highlights for Third Quarter of 2021 Fiscal Year
    Wed, March 17, 2021, 4:48 PM·7 min read

    ImmunoPrecise and Genmab enter into a technology partnership targeting infectious disease

    ImmunoPrecise and Litevax advance SARS-CoV-2 vaccine candidate for further pre-clinical evaluation

    Commenced trading on Nasdaq stock exchange

    Announced positive data from pre-clinical study of TATX-03 Polytope™ monoclonal antibody cocktail candidate against COVID-19

    IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced financial results for the third quarter of its 2021 fiscal year ended January 31, 2020.

    Q3 Fiscal 2021 Financial Highlights:

    Increased revenue for the nine months ended January 31st, 2021 by 32% to $13,035,522.

    Record adjusted EBITDA for the nine months ended January 31st, 2021 of $2,564,257, a significant increase from the $18,356 for the nine months ended January 31, 2020.

    Closed USD$21.7 million bought deal offering of common shares.

    Closed over-allotment option associated with the previously completed bought deal of USD$3.3 Million.
  • J
    Jerry
    Glad to see some excitement in the stock again.
  • b
    beurs
    Bought some more today...low volume...shorters take this down ...soon over 15 again....
  • A
    Adrian
    Thank God for a good day
  • b
    beurs
    Hope to see 15 friday..would be a good start
  • b
    beurs
    Back sub 5$?
  • J
    JohnM
    this company is resting on the 200 day exponential moving average but that will fail and it is headed much lower. The CEO is a total poser and not enough of the promised milestones have passed.
  • D
    Don
    Not sure but wonder if all the COVID vaccines reduce need for IPA’s antibody “cocktail”. Of course they make antibodies targeted at other diseases including cancer . We need to see new positive findings from IPA.
  • M
    Max
    Why nobody talks about the deal that was closed 1 years ago between IPA and J&J for COVID vaccine?!!!! Now J&J vaccine is out and also this happened thanks to IPA researchers!!
  • J
    JohnM
    Massive after hours dump. Something is not right here. The chart is telling us the company is about to announce some bad news.
  • b
    beurs
    Bought shares today and will continue if it drops more..some day it will be 25+ again..buy when there is panic..
  • T
    Trader
    Huge sell volume, looks like it might fall further.
  • R
    RC
    Covid treatment and prevention. That's extremely good news. I don't understand why weren't not on our way to the moon.